Clay TM - Search Results

1

Nishimura MI, Roszkowski JJ, Moore TV, Brasic N, McKee MD, Clay TM. Nishimura MI, et al. Among authors: clay tm. Cancer Treat Res. 2005;123:37-59. doi: 10.1007/0-387-27545-2_2. Cancer Treat Res. 2005. PMID: 16211865 Review.

2

Redirecting T lymphocyte specificity using T cell receptor genes.

Kaplan BL, Yu DC, Clay TM, Nishimura MI. Kaplan BL, et al. Among authors: clay tm. Int Rev Immunol. 2003 May-Aug;22(3-4):229-53. doi: 10.1080/08830180305227. Int Rev Immunol. 2003. PMID: 12745641 Review.

3

Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytes.

Clay TM, Nishimura MI. Clay TM, et al. Methods Mol Biol. 2003;215:227-34. doi: 10.1385/1-59259-345-3:227. Methods Mol Biol. 2003. PMID: 12512302 No abstract available.

4

Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors.

McKee MD, Clay TM, Rosenberg SA, Nishimura MI. McKee MD, et al. Among authors: clay tm. J Immunother. 1999 Mar;22(2):93-102. doi: 10.1097/00002371-199903000-00001. J Immunother. 1999. PMID: 10093034

5

Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.

McKee MD, Clay TM, Diamond RA, Rosenberg SA, Nishimura MI. McKee MD, et al. Among authors: clay tm. J Immunother. 2000 Jul-Aug;23(4):419-29. doi: 10.1097/00002371-200007000-00005. J Immunother. 2000. PMID: 10916751

6

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI. Norell H, et al. Cancer Immunol Immunother. 2010 Jun;59(6):851-62. doi: 10.1007/s00262-009-0810-8. Epub 2010 Jan 6. Cancer Immunol Immunother. 2010. PMID: 20052466 Free PMC article.

7

Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.

Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlich J, Rosenberg SA, Nishimura MI. Clay TM, et al. J Immunol. 1999 Feb 1;162(3):1749-55. J Immunol. 1999. PMID: 9973438

8

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.

Clay TM, Custer MC, Spiess PJ, Nishimura MI. Clay TM, et al. Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003. Pathol Oncol Res. 1999. PMID: 10079371 Free article. Review.

9

Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.

Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Clay TM, et al. J Immunol. 1999 Jul 1;163(1):507-13. J Immunol. 1999. PMID: 10384155

10

T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.

Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA. Nishimura MI, et al. Among authors: clay tm. J Immunother. 1998 Sep;21(5):352-62. doi: 10.1097/00002371-199809000-00003. J Immunother. 1998. PMID: 9789197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page